Adam A Zetter

Title: Adam A Zetter: Innovator in Liposome Technology

Introduction

Adam A Zetter is a notable inventor based in Menlo Park, CA (US). He has made significant contributions to the field of medical technology, particularly in the development of liposome compositions for therapeutic applications. His innovative work focuses on enhancing the effectiveness of radiosensitizers in cancer treatment.

Latest Patents

Adam A Zetter holds 1 patent for his invention titled "Liposome composition and method for administration of a radiosensitizer." This patent describes a method for administering a radiosensitizer to a tumor site in a subject. The method involves preparing liposomes composed of a vesicle-forming lipid and a lipid-derivatized radiosensitizer. In one embodiment, the radiosensitizer used is dipalmitoyl-5-iodo-2′-deoxyuridine. The patent also discloses a method for preparing the liposome composition that includes the lipid-derivatized radiosensitizer.

Career Highlights

Adam A Zetter is associated with Alza Corporation, where he has been instrumental in advancing research and development in drug delivery systems. His work has contributed to the understanding of how liposome technology can be utilized to improve therapeutic outcomes in cancer treatment.

Collaborations

Some of his notable coworkers include Kristen M Hjortsvang and James L Slater. Their collaborative efforts have further enhanced the research initiatives at Alza Corporation.

Conclusion

Adam A Zetter's innovative work in liposome technology represents a significant advancement in the field of cancer treatment. His contributions continue to influence the development of effective therapeutic strategies.